ArticleIranian journal of biotechnology2026
Therapeutic Potential of Ginkgolic Acid C17:1 in Modulating PTEN/mtDNA/TLR9 Axis for Alleviating Chronic Pseudomonas Aeruginosa Infection in Bronchiectasis.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objectives: This study aimed to investigate the therapeutic potential of GAC 17:1, a natural compound, in alleviating PA-induced airway injury by targeting the PTEN/mtDNA/TLR9 axis, thereby evaluating its role as a novel biotechnological intervention for immune modulation in bronchiectasis. Materials and Methods: A rat model of chronic PA-induced bronchial injury was established and divided into four groups: Control, PA-infected, PA-infected + GAC 17:1 (PTEN activator, 2 mg.kg Results: PA infection downregulated PTEN, elevated mtDNA/TLR9/NF-κB, increased IL-6/IL-17 and Th17 cells, reduced TGF-β and Tregs, and impaired lung function. Treatment with GAC 17:1, the plant-derived PTEN activator, effectively restored PTEN expression, suppressed mtDNA release and TLR9/NF-κB signaling, rebalanced Th17/Treg immunity, reduced inflammatory cytokines, and significantly improved pulmonary function. Conversely, PTEN inhibition worsened all parameters. Conclusions: This study demonstrates that GAC 17:1, a natural bioactive compound, exerts potent significant effects in PA-related bronchiectasis by activating PTEN and inhibiting the mtDNA/TLR9/NF-κB pathway. Our findings highlight GAC 17:1 as a promising biotechnological candidate for developing plant-derived immunomodulatory therapies against chronic airway infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.